BioLineRx Doses First GLIX1 GBM Patient, Reports $17.4M Runway
BLRX•BioLineRx dosed its first patient in the Phase 1/2a GLIX1 glioblastoma trial and demonstrated potent anti-tumor efficacy in TMZ-resistant preclinical models. The company reported $17.4 million of cash extending runway into H1 2027, while Q1 APHEXDA royalties rose to $0.5 million.
1. Q1 Financial Results
BioLineRx reported Q1 revenues of $0.5 million, up from $0.3 million year-over-year, driven by APHEXDA royalties of $0.5 million. Research and development expenses rose 55.8% to $2.5 million, while general and administrative expenses declined 13.3% to $0.9 million. The company held $17.4 million in cash, funding operations into the first half of 2027.
2. GLIX1 Clinical Milestone
The first patient was dosed in the Phase 1/2a trial of GLIX1 for recurrent and progressive glioblastoma at NYU Langone Health under the supervision of Dr. Alexandra Miller. The trial will enroll up to 30 patients across multiple centers, including Northwestern University and Moffitt Cancer Center, to establish the maximum tolerated dose and assess preliminary efficacy.
3. Preclinical Data and ASCO Plans
New in-vivo data showed GLIX1 achieved dose-dependent tumor inhibition and survival benefits in orthotopic cell-derived xenograft GBM models, and robust anti-tumor activity in TMZ-resistant patient-derived xenograft models where temozolomide was ineffective. Two abstracts selected for the ASCO Annual Meeting will highlight GLIX1’s novel mechanism, safety at maximal doses, and synergistic potential with PARP inhibitors in diverse cancers.
4. Other Pipeline Updates
Enrollment continues in the Phase 2b CheMo4METPANC trial of motixafortide combined with cemiplimab and standard chemotherapy in pancreatic ductal adenocarcinoma, with a planned interim progression-free survival analysis in 2026. APHEXDA product sales reached $2.7 million in Q1, generating $0.5 million in royalty revenues.
